Mapp Biopharmaceutical, Inc.

Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company, is a prime contractor and federal grant recipient developing monoclonal antibodies, recombinant antigens, and immunotherapies for infectious disease and biological threat countermeasures. The company operates entirely in full-and-open competition with no set-aside designations, competing on technical merit and established federal relationships across 51 prime awards and one sub award totaling $1.78 billion in combined potential value.

Mapp's federal capability portfolio centers on research, development, and manufacturing of human-derived monoclonal antibodies and antigen products. Recent representative work includes a $110.5 million delivery order from the Defense Health Agency (awarded June 6, 2025) for supply of monoclonal antibodies and viral recombinant antigens under Mapp's $2 million single-award indefinite delivery contract with DHA running through May 31, 2030; a $909.9 million cost-plus-fixed-fee definitive contract from the Office of the Assistant Secretary for Preparedness and Response (ASPR) for procurement of therapeutics for Ebola, Sudan, and Marburg viruses; and a $299 million cost-plus-fixed-fee contract with ASPR for development of MBP091, an immunotherapy for Marburg virus infection, which generated $20.4 million in SCI-reportable invoiced labor in FY2024 across 9.9 FTEs and 20,587 contractor hours. Mapp also holds federal research grants from the National Institute of Allergy and Infectious Diseases: a $993 thousand project grant awarded September 24, 2025, for development of MBP002, a monoclonal antibody for respiratory syncytial virus immunoprophylaxis in neonates and infants (CFDA 93.855, performance through August 31, 2028), and a project grant for development of a multispecific therapeutic for dengue (awarded June 9, 2025, completion January 31, 2027).

Customer concentration is dominated by the Department of Health and Human Services. ASPR accounts for 10 awards and $1.76 billion combined potential value (99% of all potential value across the award portfolio). The National Institutes of Health and its subordinate National Institute of Allergy and Infectious Diseases together account for 23 awards by count. The Defense Health Agency, the Defense Threat Reduction Agency, and the Department of the Army Materiel Command's Research, Development and Engineering Command represent the defense customer base, collectively carrying $23.5 million in combined potential value. The source identifies Mapp as registered since 2005 with over $1.2 billion in prior federal awards.

SCI-reported invoiced activity totaled $41.5 million across FY2022–FY2024, with $15.8 million in FY2022 (12.4 FTEs) and $25.6 million in FY2024 (12.0 FTEs); FY2023 carried no SCI-reportable invoicing. On federal services contracts captured in SCI, Mapp's government-paid hourly rates ran from a 10th percentile of $329.25/hr to a median of $657.60/hr and a 90th percentile of $1,149.01/hr, reflecting a technical-labor mix in applied research and experimental development. Mapp performs its own delivery across prime contracts without material subcontractor engagement — the average sub-hours share is 0%, despite 23 named subcontractors appearing across prime records in the SCI dataset. Two awards face ultimate completion within the next twenty-four months (combined potential value $28.9 million), creating recompete opportunity in the biodefense and medical countermeasures mission space.

monoclonal antibody drug development; anti-infectives